Bollard Group LLC Takes $1.51 Million Position in Vera Therapeutics, Inc. $VERA

Bollard Group LLC acquired a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 64,042 shares of the company’s stock, valued at approximately $1,509,000. Bollard Group LLC owned approximately 0.10% of Vera Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of VERA. Quantbot Technologies LP purchased a new stake in Vera Therapeutics during the second quarter worth $51,000. Quarry LP lifted its stake in shares of Vera Therapeutics by 25.0% during the 1st quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $60,000 after purchasing an additional 500 shares during the last quarter. AlphaQuest LLC boosted its position in Vera Therapeutics by 404.7% during the first quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock valued at $96,000 after purchasing an additional 3,213 shares in the last quarter. Virtus Investment Advisers LLC grew its stake in Vera Therapeutics by 14.8% in the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after purchasing an additional 539 shares during the last quarter. Finally, Fifth Third Bancorp purchased a new position in Vera Therapeutics in the second quarter valued at about $102,000. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Stock Up 5.4%

Vera Therapeutics stock opened at $44.90 on Friday. The business’s 50-day simple moving average is $30.37 and its two-hundred day simple moving average is $25.49. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. The company has a market cap of $2.87 billion, a PE ratio of -11.25 and a beta of 1.21. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $49.77.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same period in the previous year, the business posted ($0.85) EPS. Equities analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on VERA. JPMorgan Chase & Co. lowered their price target on shares of Vera Therapeutics from $53.00 to $52.00 and set an “overweight” rating on the stock in a report on Friday, November 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th. Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a report on Friday. TD Cowen increased their price objective on Vera Therapeutics from $60.00 to $73.00 and gave the company a “buy” rating in a report on Friday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, October 8th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $63.18.

Insiders Place Their Bets

In related news, SVP Joseph R. Young sold 15,000 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total transaction of $435,900.00. Following the completion of the transaction, the senior vice president directly owned 47,839 shares in the company, valued at approximately $1,390,201.34. This trade represents a 23.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 16.30% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.